» Articles » PMID: 35986269

Impact of Long-COVID on Health-related Quality of Life in Japanese COVID-19 Patients

Overview
Publisher Biomed Central
Specialty Public Health
Date 2022 Aug 19
PMID 35986269
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The empirical basis for a quantitative assessment of the disease burden imposed by long-COVID is currently scant. We aimed to inform the disease burden caused by long-COVID in Japan.

Methods: We conducted a cross sectional self-report questionnaire survey. The questionnaire was mailed to 526 eligible patients, who were recovered from acute COVID-19 in April 2021. Answers were classified into two groups; participants who have no symptom and those who have any ongoing prolonged symptoms that lasted longer than four weeks at the time of the survey. We estimated the average treatment effect (ATE) of ongoing prolonged symptoms on EQ-VAS and EQ-5D-3L questionnaire using inverse probability weighting. In addition to symptom prolongation, we investigated whether other factors (including demography, lifestyle, and acute severity) were associated with low EQ-VAS and EQ-5D-3L values, by multivariable linear regression.

Results: 349 participants reported no symptoms and 108 reported any symptoms at the time of the survey. The participants who reported any symptoms showed a lower average value on the EQ-VAS (69.9 vs 82.8, respectively) and on the EQ-5D-3L (0.85 vs 0.96, respectively) than those reporting no symptoms considering the ATE of ongoing prolonged symptoms. The ATE of ongoing prolonged symptoms on EQ-VAS was - 12.9 [95% CI - 15.9 to - 9.8], and on the EQ-5D-3L it was - 0.11 [95% CI - 0.13 to - 0.09], implying prolonged symptoms have a negative impact on patients' EQ-VAS and EQ-5D-3L score. In multivariable linear regression, only having prolonged symptoms was associated with lower scores (- 11.7 [95% CI - 15.0 to - 8.5] for EQ-VAS and - 0.10 [95% CI - 0.13 to - 0.08] for EQ-5D-3L).

Conclusions: Due to their long duration, long-COVID symptoms represent a substantial disease burden expressed in impact on health-related quality of life.

Citing Articles

Cost-effectiveness Analysis of Nirmatrelvir/Ritonavir Compared with Molnupiravir in Patients at High Risk for Progression to Severe COVID-19 in Japan.

Yuasa A, Matsuda H, Fujii Y, Mugwagwa T, Kado Y, Yoshida M J Health Econ Outcomes Res. 2025; 12(1):75-85.

PMID: 40012632 PMC: 11864595. DOI: 10.36469/001c.129067.


Evaluating health-related quality of life in Ethiopia: systematic review and meta-analysis of EQ-5D-based studies.

Tarekegn T, Gebrie D, Kassaw A, Dagne Taye A, Girmaw F, Ashagrie G Front Epidemiol. 2024; 4:1455822.

PMID: 39553423 PMC: 11563791. DOI: 10.3389/fepid.2024.1455822.


Cost-effectiveness analysis of NVX-CoV2373 COVID-19 vaccination for elderly people in Japan.

Kato M, Ono T, Deguchi H, Ohmagari N, Igarashi A Vaccine X. 2024; 19:100514.

PMID: 39108420 PMC: 11300936. DOI: 10.1016/j.jvacx.2024.100514.


Protocol for a longitudinal study examining the trajectory of COVID-19, post-COVID, multidimensional disadvantage and health-related quality of life in India: the IndiQol Project.

Sinha K, Gutacker N, Gu Y, Haagsma J, Kumar K, Aghdaee M BMJ Open. 2024; 14(7):e080985.

PMID: 39009459 PMC: 11253756. DOI: 10.1136/bmjopen-2023-080985.


The long COVID and its mental health manifestations - the review of literature.

Pietrzak P, Hanke W Int J Occup Med Environ Health. 2024; 37(3):360-380.

PMID: 38912617 PMC: 11424153. DOI: 10.13075/ijomeh.1896.02373.


References
1.
Johnston R, Jones K, Manley D . Confounding and collinearity in regression analysis: a cautionary tale and an alternative procedure, illustrated by studies of British voting behaviour. Qual Quant. 2018; 52(4):1957-1976. PMC: 5993839. DOI: 10.1007/s11135-017-0584-6. View

2.
Zhang Z, Kim H, Lonjon G, Zhu Y . Balance diagnostics after propensity score matching. Ann Transl Med. 2019; 7(1):16. PMC: 6351359. DOI: 10.21037/atm.2018.12.10. View

3.
Miyazato Y, Morioka S, Tsuzuki S, Akashi M, Osanai Y, Tanaka K . Prolonged and Late-Onset Symptoms of Coronavirus Disease 2019. Open Forum Infect Dis. 2020; 7(11):ofaa507. PMC: 7665672. DOI: 10.1093/ofid/ofaa507. View

4.
Modes M, Directo M, Melgar M, Johnson L, Yang H, Chaudhary P . Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021,.... MMWR Morb Mortal Wkly Rep. 2022; 71(6):217-223. PMC: 8830624. DOI: 10.15585/mmwr.mm7106e2. View

5.
McClure N, Al Sayah F, Xie F, Luo N, Johnson J . Instrument-Defined Estimates of the Minimally Important Difference for EQ-5D-5L Index Scores. Value Health. 2017; 20(4):644-650. DOI: 10.1016/j.jval.2016.11.015. View